PFN1 and metastatic malignant neoplasm in the lymph nodes: Within a 12-month follow-up, lymph node metastases were detected in 64.7% (11 patients out of 17) of HNSCC patients with a PFN1 level of more than 0.32 ng/mL before treatment.